Tag Archives: standard-of-care

New Combination To Eradicate Staph Aureus

CF-301 is a bacteriophage-derived lysin with potent activity against Staphylococcus aureus (“Staph aureus”) bloodstream infections. CF-301 is the first and only lysin to enter human clinical trials in the US and has recently completed a Phase 1 trial in healthy volunteers. This compound is being developed for the treatment of Staph aureus bloodstream infections (BSI; bacteremia), including endocarditis, caused by methicillin-resistant and susceptible Staphaureus (MRSA and MSSA) strains.

CLICK ON THE IMAGE TO ENJOY THE VIDEO

New drug-resistant strains of Staph aureus have been identified which demonstrate resistance against vancomycin and daptomycin, the only two standard-of-care (SOC) antibiotics indicated for the treatment of MRSA BSI in the US. CF-301 has the potential to be a first-in-class, new treatment for Staph aureus bacteremia. CF-301 has specific and rapid bactericidal activity against Staph aureus. Combinations of CF-301 with vancomycin or daptomycin increased survival significantly in animal models of disease when compared to treatment with SOC antibiotics or CF-301 alone. CF-301 targets a highly conserved region of the cell wall that is vital to bacteria, thus making resistance less likely to develop. When used in combination with SOC antibiotics, the result is a novel combination therapy that has the potential to combat the high unmet clinical need of Staph aureus infections.

Advantages are important:

  • Combination with antibiotics offers a superior treatment approach based on animal models
  • Act at least 12x faster than current antibiotics
  • Specifically kills Staph aureus and spares good bacteria
  • Clears biofilm

Source: https://www.contrafect.com/